Myriad Genetics Limps Into Fiscal 2020
A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
Myriad Genetics
MYGN
MYGN
$25.09
$0.60
2.4%
BATS BZX Real Time Price as of August 21, 2019, 4:00 p.m. EDT
View Interactive MYGN Charts
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
News & Analysis: Myriad Genetics
The Fool has written over 100 articles on Myriad Genetics.
Why Myriad Genetics, Nordstrom, and Luckin Coffee Slumped Today
Different challenges hit these companies but led to the same result.
Here's Why Myriad Genetics Is Getting Crushed Today
The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.
What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results
There wasn't much to like with the molecular diagnostics company's latest quarterly update.
Myriad Genetics Inc (MYGN) Q4 2019 Earnings Call Transcript
MYGN earnings call for the period ending June 30, 2019.
Why SunPower, Myriad Genetics, and Cirrus Logic Jumped Today
Find out how these stocks stayed higher even after a big plunge in the broader market.
Here's Why Myriad Genetics Is Soaring Today
A major insurer agreed to cover one of the company's most important genetic tests.
Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today
These stocks struggled on a mixed day on Wall Street.
